+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Preventive Medicines Market by Distribution Channels, Specialty Areas - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5637024
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Preventive Medicines Market grew from USD 376.49 billion in 2023 to USD 407.58 billion in 2024. It is expected to continue growing at a CAGR of 8.74%, reaching USD 676.98 billion by 2030.

Preventive medicines encompass strategies and interventions designed to avert the occurrence of diseases, minimize their impact, or mitigate their progression. The scope of preventive medicine includes vaccines, lifestyle counseling, health education, screenings, and prophylactic treatments aimed at chronic and infectious diseases. Its necessity has surged due to increasing healthcare costs, the prevalence of chronic diseases, and a growing emphasis on health and wellness. Applications include health promotion, disease prevention, and management across various healthcare settings, while the end-use scope is broad, encompassing hospitals, clinics, and home care environments. Significant market growth factors include technological advancements in diagnostic measures, increasing government support for preventive healthcare initiatives, and rising awareness about the benefits of maintaining a healthy lifestyle.

Recent opportunities lie in personalized medicine, driven by big data and genomics, allowing for tailored prevention strategies. The integration of digital health tools, such as telehealth, wearable technology, and AI-driven predictive analytics, presents novel possibilities for market expansion. To capitalize on these, stakeholders should invest in R&D for innovative vaccines and screening methods, foster partnerships with tech firms to enhance digital health solutions, and engage in community outreach to increase health literacy. However, the market faces limitations, such as high upfront costs, regulatory hurdles, and the challenge of shifting public perception from treatment to prevention. Additionally, healthcare access disparities remain a significant barrier in underdeveloped regions.

Innovations should focus on developing low-cost, accessible preventive solutions and leveraging machine learning to enhance diagnostic accuracy. Additionally, exploring plant-based and biodegradable vaccine carriers could align with sustainable environmental practices, offering dual benefits. The nature of the preventive medicine market is dynamic and evolving, characterized by rapid technological integration and a proactive approach to health management. Continuous investment in research and strategic collaborations will be crucial for business growth, ensuring that preventive medicine thrives as a vital component of integrated healthcare systems. By addressing these challenges and seizing opportunities, companies can lead in the transition toward a more preventative, patient-centric healthcare model.

Understanding Market Dynamics in the Preventive Medicines Market

The Preventive Medicines Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prices of medicines, medical devices, medical treatments, and surgical procedures
    • Increasing interest of pharma companies in manufacturing of preventive medicine
    • Initiatives and events to spread education about the preventive medicines
  • Market Restraints
    • Loosely defined regional confirmations referring to preventive drug
  • Market Opportunities
    • Collaborative market ecosystem
    • Technology advancement to support prescription of tailor made solutions
  • Market Challenges
    • Absence of proven evidences or studies citing preventive medicine

Exploring Porter’s Five Forces for the Preventive Medicines Market

Porter’s Five Forces framework further strengthens the insights of the Preventive Medicines Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Preventive Medicines Market

External macro-environmental factors deeply influence the performance of the Preventive Medicines Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Preventive Medicines Market

The Preventive Medicines Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Preventive Medicines Market

The Preventive Medicines Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Preventive Medicines Market

The Preventive Medicines Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Preventive Medicines Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Affymetrix, Inc, Cancer Prevention Pharmaceuticals, Inc, Dilon Technologies, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, McKesson Corporation, Medtronic PLC, Merck & Co. Inc., Myriad Genetics, Inc., Myriad Women’s Health, Inc., Novo Nordisk A\S, Omada Health, Inc., Omnicell, Inc., and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Preventive Medicines Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Distribution Channels
    • Diagnostic Centers
    • Hospitals
  • Specialty Areas
    • Aerospace Medicine
    • General Preventive Medicine
    • Occupational Medicine
    • Public Health
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prices of medicines, medical devices, medical treatments, and surgical procedures
5.1.1.2. Increasing interest of pharma companies in manufacturing of preventive medicine
5.1.1.3. Initiatives and events to spread education about the preventive medicines
5.1.2. Restraints
5.1.2.1. Loosely defined regional confirmations referring to preventive drug
5.1.3. Opportunities
5.1.3.1. Collaborative market ecosystem
5.1.3.2. Technology advancement to support prescription of tailor made solutions
5.1.4. Challenges
5.1.4.1. Absence of proven evidences or studies citing preventive medicine
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Preventive Medicines Market, by Distribution Channels
6.1. Introduction
6.2. Diagnostic Centers
6.3. Hospitals
7. Preventive Medicines Market, by Specialty Areas
7.1. Introduction
7.2. Aerospace Medicine
7.3. General Preventive Medicine
7.4. Occupational Medicine
7.5. Public Health
8. Americas Preventive Medicines Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Preventive Medicines Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Preventive Medicines Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. PREVENTIVE MEDICINES MARKET RESEARCH PROCESS
FIGURE 2. PREVENTIVE MEDICINES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. PREVENTIVE MEDICINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. PREVENTIVE MEDICINES MARKET DYNAMICS
TABLE 7. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY AEROSPACE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GENERAL PREVENTIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY OCCUPATIONAL MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PUBLIC HEALTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 20. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 22. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 23. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 24. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 25. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 31. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. AUSTRALIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 33. AUSTRALIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 34. CHINA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 35. CHINA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 36. INDIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 37. INDIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 38. INDONESIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 39. INDONESIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 40. JAPAN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 41. JAPAN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 42. MALAYSIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 43. MALAYSIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 44. PHILIPPINES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 45. PHILIPPINES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 46. SINGAPORE PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 47. SINGAPORE PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 48. SOUTH KOREA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 49. SOUTH KOREA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 50. TAIWAN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 51. TAIWAN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 52. THAILAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 53. THAILAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 54. VIETNAM PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 55. VIETNAM PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. DENMARK PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 60. DENMARK PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 61. EGYPT PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 62. EGYPT PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 63. FINLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 64. FINLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 65. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 66. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 67. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 68. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 69. ISRAEL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 70. ISRAEL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 71. ITALY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 72. ITALY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 73. NETHERLANDS PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 74. NETHERLANDS PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 75. NIGERIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 76. NIGERIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 77. NORWAY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 78. NORWAY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 79. POLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 80. POLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 81. QATAR PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 82. QATAR PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 84. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 85. SAUDI ARABIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 86. SAUDI ARABIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 89. SPAIN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 90. SPAIN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 91. SWEDEN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 92. SWEDEN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 93. SWITZERLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 94. SWITZERLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 95. TURKEY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 96. TURKEY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
TABLE 101. PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 102. PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Preventive Medicines Market, which are profiled in this report, include:
  • Aetna Inc.
  • Affymetrix, Inc
  • Cancer Prevention Pharmaceuticals, Inc
  • Dilon Technologies, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • McKesson Corporation
  • Medtronic PLC
  • Merck & Co. Inc.
  • Myriad Genetics, Inc.
  • Myriad Women’s Health, Inc.
  • Novo Nordisk A\S
  • Omada Health, Inc.
  • Omnicell, Inc.
  • Pfizer, Inc.

Methodology

Loading
LOADING...

Table Information